Dr. Dennis Kim - CML - Chronic myeloid leukemia
Dennis Kim, MD, PhDClinician Investigator,
Princess Margaret Cancer Centre
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Extract of UHN Research
Publication
Are we ready to use precision medicine in chronic myeloid leukemia practice?
December 2019, Haematologica
Are we ready to use precision medicine in chronic myeloid leukemia practice?
December 2019, Haematologica
ARTICLES
Doubling time after first attempt of imatinib discontinuation is helpful to identify the best candidate for the second attempt for treatment free remission with dasatinib: Canadian trad trial
June 14, 2019, EHA 2019
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase
March 12, 2014, American Journal of Hematology
Significant Discrepancy In Peripheral Blood Compared to Bone Marrow BCR-ABL Transcript Levels In Chronic Phase Chronic Myeloid Leukemia (CML)
November 19, 2010, Blood Journal
Doubling time after first attempt of imatinib discontinuation is helpful to identify the best candidate for the second attempt for treatment free remission with dasatinib: Canadian trad trial
June 14, 2019, EHA 2019
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase
March 12, 2014, American Journal of Hematology
Significant Discrepancy In Peripheral Blood Compared to Bone Marrow BCR-ABL Transcript Levels In Chronic Phase Chronic Myeloid Leukemia (CML)
November 19, 2010, Blood Journal
